Literature DB >> 29071398

[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data].

J E Gschwend1, P Albers2, M Bögemann3, P Goebell4, A Heidenreich5, J Klier6, F König7, S Machtens8, K Pantel9, C Thomas10.   

Abstract

BACKGROUND: At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented.
OBJECTIVES: The focus is on the clinical impact of these data.
MATERIALS AND METHODS: A group of German experts in the field of urogenital-oncologic expertise discussed the clinical impact with respect to the current data.
RESULTS: The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC.
CONCLUSIONS: Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20 mg/m2 cabazitaxel.

Entities:  

Keywords:  Cabazitaxel; Docetaxel; Patient selection; Prostate cancer, metastatic castration-resistant; Therapy, endocrine

Mesh：

Substances：

Year:  2018        PMID： 29071398     DOI： 10.1007/s00120-017-0533-y

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  13 in total

Review 1.  Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.

Authors:  Francesca Maines; Orazio Caffo; Antonello Veccia; Chiara Trentin; Giampaolo Tortora; Enzo Galligioni; Emilio Bria
Journal:  Crit Rev Oncol Hematol       Date:  2015-08-01       Impact factor: 6.312

2.  Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.

Authors:  Robert J van Soest; Ellen S de Morrée; Liji Shen; Ian F Tannock; Mario A Eisenberger; Ronald de Wit
Journal:  Eur Urol       Date:  2013-08-11       Impact factor: 20.096

3.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-09-18       Impact factor: 41.316

4.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

5.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

6.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.

Authors:  Axel Heidenreich; Hans-Jörg Scholz; Sebastian Rogenhofer; Christian Arsov; Margitta Retz; Stefan C Müller; Peter Albers; Jürgen Gschwend; Manfred Wirth; Ursula Steiner; Kurt Miller; Elmar Heinrich; Lutz Trojan; Björn Volkmer; Friedhelm Honecker; Carsten Bokemeyer; Bastian Keck; Burkhard Otremba; Evelyne Ecstein-Fraisse; David Pfister
Journal:  Eur Urol       Date:  2012-09-03       Impact factor: 20.096

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

10.  Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients.

Authors:  S Oudard; E Banu; F Scotte; A Banu; J Medioni; P Beuzeboc; F Joly; J-M Ferrero; F Goldwasser; J-M Andrieu
Journal:  Ann Oncol       Date:  2007-09-09       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.